Breaking News Instant updates and real-time market news.

MRK

Merck

$62.21

0.57 (0.92%)

07:01
11/28/16
11/28
07:01
11/28/16
07:01

Merck's sBLA for Keytruda granted priority review by FDA

Merck announced that the U.S. FDA accepted for review the supplemental Biologics License Application for KEYTRUDA, the company's anti-PD-1 therapy, for the treatment of previously treated patients with advanced microsatellite instability-high cancer. The FDA granted Priority Review with a PDUFA, or target action date, of March 8, 2017; the sBLA will be reviewed under the FDA's Accelerated Approval program based on tumor response rate and durability of response. The FDA recently granted Breakthrough Therapy Designation to KEYTRUDA for unresectable or metastatic MSI-H non-colorectal cancer, and previously granted it for the treatment of patients with unresectable or metastatic MSI-H colorectal cancer. The application, which is seeking approval for KEYTRUDA at a fixed dose of 200 mg every three weeks, is based on data from five uncontrolled, open-label, multi-cohort, multi-site phase I/II trials investigating the activity of KEYTRUDA in MSI-H cancer.

  • 29

    Nov

  • 03

    Dec

MRK Merck
$62.21

0.57 (0.92%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
10/24/16
RHCO
10/24/16
NO CHANGE
RHCO
Merck Keytruda to have several positive catalysts, says SunTrust
SunTrust analyst John Boris says that several trials of Merck's Keytruda will be stopped early "across multiple tumor types," providing a positive catalyst. Boris says that Keytruda should be approved for 1LNSCLC on or before December 24 and KN-21 chemo combo compendium listing in 1H17. He keeps a $73 price target and Buy rating on Merck.
10/25/16
RHCO
10/25/16
NO CHANGE
RHCO
Merck shares should be bought after early FDA approval, says SunTrust
After Merck announced that the FDA had approved the company's Keytruda treatment for the first-line metastatic non-small cell lung cancer with tumor proportion scores of 50% or higher, SunTrust analyst John Boris says that such patients represent about 30% "of the prevalent first-line population." He adds that the approval was earlier than expected and gives Keytruda an approximately 15 month lead over competing drugs in NSCLC. The analyst thinks that the early approval will enable the company's 2021 revenue to beat expectations by a significant amount, and he recommends buying the stock on the news.

TODAY'S FREE FLY STORIES

NCR

NCR Corp.

$40.15

1.51 (3.91%)

08:13
06/27/17
06/27
08:13
06/27/17
08:13
Hot Stocks
MFA Oil implements NCR OPTIC 5 solution across 73 locations »

NCR Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMTX

Dimension Therapeutics

$1.55

0.1 (6.90%)

08:13
06/27/17
06/27
08:13
06/27/17
08:13
Hot Stocks
Dimension Therapeutics completes strategic review, updates corporate priorities »

Dimension Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTY

Getty Realty

$25.05

0.21 (0.85%)

08:11
06/27/17
06/27
08:11
06/27/17
08:11
Hot Stocks
Getty Realty enters definitive agreement to acquire 49 properties for $123M »

Getty Realty announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENE

Xenon Pharmaceuticals

$3.80

-0.3 (-7.32%)

08:10
06/27/17
06/27
08:10
06/27/17
08:10
Hot Stocks
Breaking Hot Stocks news story on Xenon Pharmaceuticals »

Xenon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABIL

Ability

$1.40

0.14 (11.11%)

08:09
06/27/17
06/27
08:09
06/27/17
08:09
Hot Stocks
Ability regains Nasdaq listing compliance »

Ability received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCYT

Veracyte

$7.90

0.14 (1.80%)

08:09
06/27/17
06/27
08:09
06/27/17
08:09
Hot Stocks
Veracyte says study published supporting Envisia Genomic Classifier »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$53.74

-0.59 (-1.09%)

08:08
06/27/17
06/27
08:08
06/27/17
08:08
Recommendations
PayPal analyst commentary  »

PayPal could free up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

RCII

Rent-A-Center

$11.48

0.28 (2.50%)

08:08
06/27/17
06/27
08:08
06/27/17
08:08
Hot Stocks
Rent-A-Center names Martin Evans chief human resources officer »

Rent-A-Center announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$248.91

2.45 (0.99%)

08:07
06/27/17
06/27
08:07
06/27/17
08:07
Hot Stocks
Allergan launches Refresh Optive Mega-3 artificial tears »

Allergan launched the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSTG

Biostage

$0.34

0.025 (7.94%)

08:07
06/27/17
06/27
08:07
06/27/17
08:07
Syndicate
Biostage raises $3.1M in a private placement »

Biostage announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBVX

MabVax Therapeutics

$1.46

-0.0775 (-5.04%)

08:06
06/27/17
06/27
08:06
06/27/17
08:06
Hot Stocks
MabVax Therapeutics begins dosing in Phase 1 clinical trial evaluating MVT-1075 »

MabVax Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPLD

Upland Software

$22.29

-0.21 (-0.93%)

08:06
06/27/17
06/27
08:06
06/27/17
08:06
Initiation
Upland Software initiated  »

Upland Software initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVIV

InVivo Therapeutics

$2.55

-0.3 (-10.53%)

08:05
06/27/17
06/27
08:05
06/27/17
08:05
Hot Stocks
InVivo Therapeutics announces new patient enrollment in INSPIRE study »

InVivo Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PHG

Philips

$36.74

-0.12 (-0.33%)

08:04
06/27/17
06/27
08:04
06/27/17
08:04
Hot Stocks
Philips receives FDA 510(k) clearance to market IntelliSpace Portal 9.0 »

Royal Philips announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$90.08

1.35 (1.52%)

08:03
06/27/17
06/27
08:03
06/27/17
08:03
Technical Analysis
Technical View: Darden trades near 52-week high after earnings »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 18

    Jul

  • 19

    Jul

KSS

Kohl's

$37.52

0.49 (1.32%)

, SVU

Supervalu

$3.03

0.09 (3.06%)

08:03
06/27/17
06/27
08:03
06/27/17
08:03
Hot Stocks
Kohl's appoints Bruce Besanko as CFO »

Kohl's (KSS)…

KSS

Kohl's

$37.52

0.49 (1.32%)

SVU

Supervalu

$3.03

0.09 (3.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$65.92

-0.24 (-0.36%)

, SNY

Sanofi

$49.59

0.26 (0.53%)

08:03
06/27/17
06/27
08:03
06/27/17
08:03
Recommendations
Merck, Sanofi, Johnson & Johnson, Bristol-Myers, Pfizer, Roche, Novartis, AstraZeneca, GlaxoSmithKline, Eli Lilly analyst commentary  »

Large cap pharma could…

MRK

Merck

$65.92

-0.24 (-0.36%)

SNY

Sanofi

$49.59

0.26 (0.53%)

JNJ

Johnson & Johnson

$136.34

-0.09 (-0.07%)

BMY

Bristol-Myers

$56.92

0.28 (0.49%)

PFE

Pfizer

$34.04

-0.13 (-0.38%)

RHHBY

Roche

$32.47

-0.29 (-0.89%)

NVS

Novartis

$85.75

-0.59 (-0.68%)

AZN

AstraZeneca

$35.15

0.08 (0.23%)

GSK

GlaxoSmithKline

$44.07

-0.22 (-0.50%)

LLY

Eli Lilly

$84.28

0.39 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 11

    Jul

  • 12

    Jul

  • 13

    Jul

  • 18

    Jul

  • 27

    Jul

  • 30

    Jul

  • 02

    Aug

  • 27

    Aug

  • 22

    Sep

  • 24

    Sep

NFEC

NF Energy

$0.92

0.01 (1.10%)

08:02
06/27/17
06/27
08:02
06/27/17
08:02
Hot Stocks
NF Energy signs $600K valve sales contract »

NF Energy signed a $600K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$1.12

-0.02 (-1.75%)

08:02
06/27/17
06/27
08:02
06/27/17
08:02
Hot Stocks
Trovagene submits IND application to FDA for Phase 1b/2 trial of PCM-075 »

Trovagene announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWKS

Skyworks

$101.32

-3.04 (-2.91%)

08:00
06/27/17
06/27
08:00
06/27/17
08:00
Options
Skyworks put buyer realizes 14% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHAK

Shake Shack

$35.54

-1.46 (-3.95%)

07:59
06/27/17
06/27
07:59
06/27/17
07:59
Recommendations
Shake Shack analyst commentary  »

Shake Shack Q2 comps may…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$117.80

0.78 (0.67%)

, BAYRY

Bayer

$136.70

0.34 (0.25%)

07:56
06/27/17
06/27
07:56
06/27/17
07:56
Downgrade
Monsanto, Bayer rating change  »

Monsanto downgraded to…

MON

Monsanto

$117.80

0.78 (0.67%)

BAYRY

Bayer

$136.70

0.34 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

07:55
06/27/17
06/27
07:55
06/27/17
07:55
General news
U.S. chain store sales climbed 2.9% in the week ended June 24 »

U.S. chain store sales…

RARX

RA Pharmaceuticals

$22.18

-0.83 (-3.61%)

07:55
06/27/17
06/27
07:55
06/27/17
07:55
Conference/Events
RA Pharmaceuticals to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

WDC

Western Digital

$92.66

-0.68 (-0.73%)

07:54
06/27/17
06/27
07:54
06/27/17
07:54
Recommendations
Western Digital analyst commentary  »

Morgan Stanley has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.